MedPath

Famotidine

Generic Name
Famotidine
Brand Names
Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
Drug Type
Small Molecule
Chemical Formula
C8H15N7O2S3
CAS Number
76824-35-6
Unique Ingredient Identifier
5QZO15J2Z8
Background

Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and eight times more potent than ranitidine on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.

Indication

Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.

It is also indicated in adult patients for the treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasias) and reduction of the risk of DU recurrence.

The intravenous formulation of famotidine is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.

Over-the-counter famotidine is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults. Off-label uses of famotidine include the reduction of NSAIDs-associated gastrointestinal effects, treatment of refractory urticarial, prevention of stress ulcer in critically-ill patients, and symptomatic relief of gastritis.

Associated Conditions
Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions

Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit

Phase 4
Completed
Conditions
Ulcer
Interventions
First Posted Date
2008-03-11
Last Posted Date
2013-10-16
Lead Sponsor
Far Eastern Memorial Hospital
Target Recruit Count
60
Registration Number
NCT00633035
Locations
🇨🇳

Far Eastern Memorial Hospital, Taipei, Taiwan

Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo (Microcrystallized cellulose)
First Posted Date
2007-11-29
Last Posted Date
2012-03-20
Lead Sponsor
Jesper Ekelund
Target Recruit Count
30
Registration Number
NCT00565175
Locations
🇫🇮

Kellokosken sairaala, Kellokoski, Finland

🇫🇮

Vaasa Hospital District, Vaasa, Finland

🇫🇮

Lohjan sairaanhoitoalue, Lohja, Finland

and more 2 locations

Ulcer Prevention Study in Post Gastric Bypass Patients

Phase 4
Completed
Conditions
Marginal Ulcers
Interventions
First Posted Date
2007-11-14
Last Posted Date
2017-01-19
Lead Sponsor
University of Missouri-Columbia
Target Recruit Count
40
Registration Number
NCT00557349
Locations
🇺🇸

University of Missouri Health Care, Columbia, Missouri, United States

Study of XL281 in Adults With Solid Tumors

Phase 1
Completed
Conditions
Cancer
Non-small-cell Lung Cancer
Colorectal Cancer
Papillary Thyroid Cancer
Melanoma
Interventions
First Posted Date
2007-03-26
Last Posted Date
2011-10-13
Lead Sponsor
Exelixis
Target Recruit Count
180
Registration Number
NCT00451880
Locations
🇺🇸

Sarah Cannon Research Institute, Nashville, Tennessee, United States

🇺🇸

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 3 locations

Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients

Phase 4
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2006-10-06
Last Posted Date
2010-02-05
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
40
Registration Number
NCT00384904
Locations
🇬🇧

Local Institution, London, Greater London, United Kingdom

🇺🇸

Garden State Infectious Disease Associates, Pa, Voorhees, New Jersey, United States

🇺🇸

Unc Center For Aids Research, Chapel-Hill, North Carolina, United States

Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -

Phase 3
Completed
Conditions
Gastroesophageal Reflux
Interventions
First Posted Date
2005-09-29
Last Posted Date
2011-07-07
Lead Sponsor
Taiho Pharmaceutical Co., Ltd.
Target Recruit Count
325
Registration Number
NCT00229424
Locations
🇯🇵

Tohoku University Hospital, 1-1, Seiryo-cho, Aoba-ku, Sendai, Miyagi, Japan

Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease

Phase 2
Completed
Conditions
Gastroesophageal Reflux
First Posted Date
2005-09-02
Last Posted Date
2011-11-21
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
480
Registration Number
NCT00141960
© Copyright 2025. All Rights Reserved by MedPath